Anil Pareek, Franz H. Messerli, Gustavo Saravia, Ravi Tejraj Mehta
{"title":"美洲心脏病学会(IASC)立场声明:氯噻酮与噻嗪类利尿剂","authors":"Anil Pareek, Franz H. Messerli, Gustavo Saravia, Ravi Tejraj Mehta","doi":"10.1016/j.ijchy.2020.100054","DOIUrl":null,"url":null,"abstract":"<div><p>The Interamerican Society of Cardiology (IASC) Position Statement for hypertension management in Latin America is a practical and useful review of five different hypertension guidelines. Though, thiazide diuretics have been recommended as firstline option, the position statement needs to highlight differences <em>within</em> the thiazide class. Chlorthalidone is structurally and pharmacokinetically distinct from thiazide-<em>type</em> iuretics like hydrochlorothiazide with a longer half-life and 24-h anti-hypertensive effect. It has been shown to reduce cardiovascular morbidity and mortality in several landmark studies evaluating anti-hypertensives.</p></div>","PeriodicalId":36839,"journal":{"name":"International Journal of Cardiology: Hypertension","volume":"7 ","pages":"Article 100054"},"PeriodicalIF":0.0000,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ijchy.2020.100054","citationCount":"1","resultStr":"{\"title\":\"Interamerican Society of Cardiology (IASC) position statement: Chlorthalidone vs. thiazide-type diuretics\",\"authors\":\"Anil Pareek, Franz H. Messerli, Gustavo Saravia, Ravi Tejraj Mehta\",\"doi\":\"10.1016/j.ijchy.2020.100054\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>The Interamerican Society of Cardiology (IASC) Position Statement for hypertension management in Latin America is a practical and useful review of five different hypertension guidelines. Though, thiazide diuretics have been recommended as firstline option, the position statement needs to highlight differences <em>within</em> the thiazide class. Chlorthalidone is structurally and pharmacokinetically distinct from thiazide-<em>type</em> iuretics like hydrochlorothiazide with a longer half-life and 24-h anti-hypertensive effect. It has been shown to reduce cardiovascular morbidity and mortality in several landmark studies evaluating anti-hypertensives.</p></div>\",\"PeriodicalId\":36839,\"journal\":{\"name\":\"International Journal of Cardiology: Hypertension\",\"volume\":\"7 \",\"pages\":\"Article 100054\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/j.ijchy.2020.100054\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Cardiology: Hypertension\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2590086220300318\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Cardiology: Hypertension","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2590086220300318","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
Interamerican Society of Cardiology (IASC) position statement: Chlorthalidone vs. thiazide-type diuretics
The Interamerican Society of Cardiology (IASC) Position Statement for hypertension management in Latin America is a practical and useful review of five different hypertension guidelines. Though, thiazide diuretics have been recommended as firstline option, the position statement needs to highlight differences within the thiazide class. Chlorthalidone is structurally and pharmacokinetically distinct from thiazide-type iuretics like hydrochlorothiazide with a longer half-life and 24-h anti-hypertensive effect. It has been shown to reduce cardiovascular morbidity and mortality in several landmark studies evaluating anti-hypertensives.